SI9500329A - Quinoxalines, process for the preparation thereof and use thereof - Google Patents

Quinoxalines, process for the preparation thereof and use thereof Download PDF

Info

Publication number
SI9500329A
SI9500329A SI9500329A SI9500329A SI9500329A SI 9500329 A SI9500329 A SI 9500329A SI 9500329 A SI9500329 A SI 9500329A SI 9500329 A SI9500329 A SI 9500329A SI 9500329 A SI9500329 A SI 9500329A
Authority
SI
Slovenia
Prior art keywords
formula
compounds
cooch
cooc
alkoxy
Prior art date
Application number
SI9500329A
Other languages
English (en)
Slovenian (sl)
Inventor
Manfred Dr Roesner
Uta-Maria Billhardt-Troughton
Reinhard Dr Kirsch
Joerg-Peter Dr Kleim
Christoph Dr Meichsner
Guenther Dr Ries
Irvin Dr Winkler
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of SI9500329A publication Critical patent/SI9500329A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Dental Preparations (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compounds Of Unknown Constitution (AREA)
SI9500329A 1994-10-19 1995-10-19 Quinoxalines, process for the preparation thereof and use thereof SI9500329A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4437406A DE4437406A1 (de) 1994-10-19 1994-10-19 Chinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung

Publications (1)

Publication Number Publication Date
SI9500329A true SI9500329A (en) 1996-04-30

Family

ID=6531202

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9500329A SI9500329A (en) 1994-10-19 1995-10-19 Quinoxalines, process for the preparation thereof and use thereof

Country Status (28)

Country Link
US (1) US5723461A (xx)
EP (1) EP0708093B1 (xx)
JP (1) JPH08225544A (xx)
KR (1) KR960014108A (xx)
CN (1) CN1094930C (xx)
AT (1) ATE198747T1 (xx)
AU (1) AU708293B2 (xx)
BR (1) BR9504456A (xx)
CA (1) CA2160859A1 (xx)
CZ (1) CZ271295A3 (xx)
DE (2) DE4437406A1 (xx)
DK (1) DK0708093T3 (xx)
ES (1) ES2154311T3 (xx)
FI (1) FI954946A (xx)
GR (1) GR3035673T3 (xx)
HK (1) HK1011988A1 (xx)
HR (1) HRP950524B1 (xx)
HU (1) HUT73485A (xx)
IL (1) IL115641A0 (xx)
MY (1) MY132057A (xx)
NO (1) NO306615B1 (xx)
NZ (1) NZ280258A (xx)
PL (1) PL184860B1 (xx)
PT (1) PT708093E (xx)
SI (1) SI9500329A (xx)
SK (1) SK128495A3 (xx)
TW (1) TW328954B (xx)
ZA (1) ZA958783B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369057B1 (en) * 1991-04-15 2002-04-09 Aventis Pharma Deutschland Gmbh Quinoxalines, processes for their preparation and their use
US6015800A (en) * 1997-09-03 2000-01-18 Warner-Lambert Company Substituted quinoxaline-2-ones as glutamate receptor antagonists
WO1999025327A2 (en) * 1997-11-14 1999-05-27 Warner-Lambert Company Small molecule intervention in hiv-1 replication
GB9901795D0 (en) * 1999-01-28 1999-03-17 Glaxo Group Ltd Chemical compounds
GB9911887D0 (en) * 1999-05-21 1999-07-21 Glaxo Group Ltd Methods and medicaments for post exposure prophylaxis of an hiv infection
US20030114385A1 (en) * 2001-04-27 2003-06-19 Cathers Brian E. Viral enzyme activated prototoxophores and use of same to treat viral infections
WO2005018531A2 (fr) * 2003-08-26 2005-03-03 'chemical Diversity Research Institute', Ltd. Compositions pharmaceutiques, composes azo-heterocycliques et procedes de fabrication et d'utilisation correspondants
US7351709B2 (en) * 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
PT2841428T (pt) 2012-04-24 2018-11-29 Vertex Pharma Inibidores de adn-pk
EP3985003B1 (en) 2013-03-12 2023-08-09 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
CN105814036B (zh) 2013-10-17 2018-10-26 沃泰克斯药物股份有限公司 作为dna-pk抑制剂的共晶
KR20190062485A (ko) 2016-09-27 2019-06-05 버텍스 파마슈티칼스 인코포레이티드 Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT509398E (pt) * 1991-04-15 2002-02-28 Aventis Pharma Gmbh Quinoxalinas processo para a sua preparacao e sua utilizacao
DE4342024A1 (de) * 1993-12-09 1995-06-14 Hoechst Ag Kombinationspräparate, enthaltend ein Chinoxalin und ein Nukleosid

Also Published As

Publication number Publication date
HRP950524B1 (en) 2002-06-30
DK0708093T3 (da) 2001-04-30
NO954139D0 (no) 1995-10-18
GR3035673T3 (en) 2001-06-29
KR960014108A (ko) 1996-05-22
FI954946A (fi) 1996-04-20
AU3431695A (en) 1996-05-02
TW328954B (en) 1998-04-01
NO954139L (no) 1996-04-22
ATE198747T1 (de) 2001-02-15
NO306615B1 (no) 1999-11-29
CN1094930C (zh) 2002-11-27
CN1135483A (zh) 1996-11-13
HUT73485A (en) 1996-08-28
CZ271295A3 (en) 1996-08-14
FI954946A0 (fi) 1995-10-17
HU9503005D0 (en) 1995-12-28
PL311016A1 (en) 1996-04-29
SK128495A3 (en) 1996-06-05
PL184860B1 (pl) 2003-01-31
AU708293B2 (en) 1999-07-29
BR9504456A (pt) 1997-05-20
IL115641A0 (en) 1996-01-19
HRP950524A2 (en) 1997-10-31
MY132057A (en) 2007-09-28
ZA958783B (en) 1996-05-09
JPH08225544A (ja) 1996-09-03
ES2154311T3 (es) 2001-04-01
DE4437406A1 (de) 1996-04-25
DE59508969D1 (de) 2001-02-22
EP0708093B1 (de) 2001-01-17
US5723461A (en) 1998-03-03
NZ280258A (en) 1997-09-22
EP0708093A1 (de) 1996-04-24
PT708093E (pt) 2001-06-29
CA2160859A1 (en) 1996-04-20
HK1011988A1 (en) 1999-07-23

Similar Documents

Publication Publication Date Title
CA3030510C (en) Azole dione compounds with anti-cancer activity
EP0590428B1 (de) Azachinoxaline, Verfahren zu ihrer Herstellung und ihre Verwendung
EP2415767B1 (en) Poly (ADP-ribose) Polymerase (PARP) Inhibitors
SI9500329A (en) Quinoxalines, process for the preparation thereof and use thereof
US9624220B2 (en) Compounds and method for treatment of HIV
WO2021018003A1 (zh) Egfr抑制剂、组合物及其制备方法
KR950001015B1 (ko) 술폭시드 유도체의 제조방법
ES2282234T3 (es) Derivados de la tirosina con actividad anti-leucotrienos.
KR20080035594A (ko) 크산틴옥시다아제 저해제
EP0144730B1 (en) 2-anilino-1,6-dihydro-6-oxo-5-pyrimidinecarboxylic acid derivatives, processes for the preparation thereof, and antiallergic agent containing the same
AU8545091A (en) Antiproliferative substituted naphthalene compounds
FI73673B (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla 1,5-difenylpyrazolin-3-on-foereningar.
JP2000508299A (ja) 抗ウイルス作用を有する置換キノリン誘導体
US20230391753A1 (en) Thiobenzimidazole derivative or pharmaceutically acceptable salt thereof and use thereof
WO2022199367A1 (zh) 氨基二硫代甲酸酯类化合物及其制备方法和药物组合物及应用
CN111393366B (zh) 四氢异喹啉类衍生物、制备方法、药物组合物及应用
CS236896B2 (en) Processing of new 4-hydroxy-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxide
JPS63183577A (ja) ベンズイミダゾ−ル誘導体
JPH0372480A (ja) キサンチン誘導体及びそれらを有効成分とする気管支拡張剤
HU212266B (en) Process for producing novel 1,3,4-benzotriazepin-5(4h)-one derivatives and pharmaceutical preparations containing them
Dandegaonker et al. Quinoxaline Sulfonamides
PL127345B1 (en) Method of obtaining derivatives of 9-hydrazone-6,7,8,9-tetrahydro-4h-pyrido/1,2,-a/ pyrimidi-4-none
DE4142322A1 (de) Chinoxaline, verfahren zu ihrer herstellung und ihreverwendung